D-0533-2023 Class II Ongoing

Recalled by Ascend Laboratories, LLC — Parsippany, NJ

FDA drug recall D-0533-2023 was initiated by Ascend Laboratories, LLC on Mar 14, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit. The recall status is ongoing. Affected quantity: 13,560 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 5, 2023
Initiation Date
Mar 14, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
13,560 bottles

Product description

Dabigatran Etexilate Capsules, 75 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-474-60.

Reason for recall

CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.

Distribution pattern

Nationwide in the USA.

Code information

Lot #s: 22142462, 22142463, 22142464, Exp 5/2024; 22143000, 22143001, 22143002, Exp 6/2024.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0533-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0533-2023. Report a data issue: hello@regdatalab.com.